77 -5 (55) 2023 — Kuryazov A.M., Boboev K.T. — CLINICAL SIGNIFICANCE OF GENOTYPIC VARIANTS OF THE POLYMORPHIC TP53 GENE (RS1042522) IN DETERMINING THE RISK OF DEVELOPING HEMOBLASTOSES

CLINICAL SIGNIFICANCE OF GENOTYPIC VARIANTS OF THE POLYMORPHIC TP53 GENE (RS1042522) IN DETERMINING THE RISK OF DEVELOPING HEMOBLASTOSES

Kuryazov A.M., Republican Specialized Scientific and Practical Medical Hematology Center, Uzbekistan Tashkent

Boboev K.T., Republican Specialized Scientific and Practical Medical Hematology Center, Uzbekistan Tashkent

AbdurakhmonovaSh.A. Republican Specialized Scientific and Practical Medical Hematology Center, Uzbekistan Tashkent

Resume

In this scientific research, we have studied the frequency of occurrence of TP53 gene polymorphisms in hemoblastoses compared with a healthy population to determine the risk of developing oncopathology.

Conducting molecular genetic studies of the rs1042522 polymorphism of the TP53 gene in a group of patients and healthy individuals with respect to hemoblastosis revealed the significance of the Pro/Pro genotype homozygous for the mutant allele for the risk of developing oncohematological disease.

Key words: hemoblastosis, TP53 gene, genotype, polymorphism, mutation.

First page

439

Last page

443

For citation: Kuryazov A.M., Boboev K.T., AbdurakhmonovaSh.A. – CLINICAL SIGNIFICANCE OF GENOTYPIC VARIANTS OF THE POLYMORPHIC TP53 GENE (RS1042522) IN DETERMINING THE RISK OF DEVELOPING HEMOBLASTOSES //New Day in Medicine 2023 5(55): 439-443 https://newdaymedicine.com/index.php/2023/06/12/l-126/

LIST OF REFERENCES:

1. Виноградов А.В., Резайкин А.В., Литвинова Д.В., Лобода А.Н., Сазонов С.В., Сергеев А.Г. Патогенетическое значение точечных мутаций гена ТР53 при острых миелоидных лейкозах взрослых Российский иммунологический журнал, 2020 23(2):195-202.
2. Bellamy WT, Richter L, Sirjam D et al Vascular endothehal cell growth factor is an autocnne promoter of abnormal localized immature myeloid precursors and leukemia pro genitor formation in myelodysplastic syndromes  Blood 2001 97:1427-1434.
3. Eroğlu C. et al. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines Tumor Biology. 2015 36:9437-9446.
4. Herold T. et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia Leukemia. 2020 34(12):3161-3172..
5. Huang R., Liao X., Li Q. Identification of key pathways and genes in TP53 mutation acute myeloid leukemia:evidence from bioinformatics analysis OncoTargets Ther.,2017 11:163-173.
6. Hunter A.M., Sallman D.A. Current status and new treatment approaches in TP53 mutated AML.  Best Pract. Res. Clin. Haematol., 2019 32(2):134-144.
7. McGowan-Jordan J. (ed.). ISCN 2016: an international system for human cytogenomic nomenclature (2016) recommendations of the international standing human committee on human cytogenomic nomenclature including new sequence-based cytogenomic. – Karger, 2016 1-150.
8. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996 2:1731-1741.
9. Welch J.S. Patterns of mutations in TP53 mutated AML.  Best Pract. Res. Clin. Haematol., 2018 31(4):379-383.